Taxanes in the Treatment of Advanced Gastric Cancer

被引：16
作者：
Kang, Byung Woog [1 ]
Kwon, Oh-Kyoung [2 ]
Chung, Ho Young [2 ]
Yu, Wansik [2 ]
Kim, Jong Gwang [1 ]
机构：
[1] Kyungpook Natl Univ, Dept Oncol Hematol, Med Ctr, Sch Med,Canc Res Inst, 807 Hogukno, Daegu 41404, South Korea
[2] Kyungpook Natl Univ, Dept Surg, Kyungpook Natl Univ Hosp, Sch Med, Daegu 41494, South Korea
来源：
MOLECULES | 2016年 / 21卷 / 05期
基金：
新加坡国家研究基金会;
关键词：
gastric cancer; taxanes; paclitaxel; docetaxel; chemotherapy; PHASE-III TRIAL; ALBUMIN-BOUND PACLITAXEL; 2ND-LINE CHEMOTHERAPY; 1ST-LINE THERAPY; PLUS CISPLATIN; ANTITUMOR-ACTIVITY; OPEN-LABEL; FLUOROURACIL; DOCETAXEL; ADENOCARCINOMA;
D O I：
10.3390/molecules21050651
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Although rapid advances in treatment options have improved the prognosis of advanced gastric cancer (AGC), it remains a major public health problem and the second leading cause of cancer-related deaths in the world. Taxanes (paclitaxel and docetaxel) are microtubule stabilizing agents that inhibit the process of cell division, and have shown antitumor activity in the treatment of AGC as a single or combination chemotherapy. Accordingly, this review focuses on the efficacy and tolerability of taxanes in the first-or second-line chemotherapy setting for AGC.
引用
收藏
页数：10
相关论文
共 50 条
  • [31] The role of taxanes in the treatment of breast cancer
    Nabholtz, JM
    Gligorov, J
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (07) : 1073 - 1094
  • [32] The application of immunotherapy combined with taxanes in second-line treatment of advanced HER2 negative gastric cancer
    Chen, Tianran
    Xu, Meng
    Xu, Jiajun
    Zhan, Xianbao
    Zhang, Yingyi
    Ying, Mingzhen
    Wu, Meihong
    MOLECULAR AND CLINICAL ONCOLOGY, 2025, 22 (01)
  • [33] Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer
    Kohei Shitara
    Keitaro Matsuo
    Ayako Mizota
    Chihiro Kondo
    Motoo Nomura
    Daisuke Takahari
    Tomoya Yokota
    Takashi Ura
    Seiji Ito
    Akira Sawaki
    Masahiro Tajika
    Hiroki Kawai
    Kei Muro
    Gastric Cancer, 2011, 14 : 155 - 160
  • [34] Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
    Rivera, Edgardo
    Cianfrocca, Mary
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 659 - 670
  • [35] Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer
    Shi, Chunmei
    Chen, Qiang
    Shen, Songfei
    Wu, Riping
    Yang, Baoyu
    Liu, Qing
    Xu, Qian
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (05) : 595 - 601
  • [36] Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2+Advanced Gastric Cancer: A Retrospective Study
    Tong, Gangling
    Li, Shuluan
    Lin, Lin
    He, Lirui
    Wang, Li
    Lv, Guoqing
    Zheng, Ruinian
    Wang, Shubin
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 2481 - 2489
  • [37] Optimising treatment regimens for the management of advanced gastric cancer
    Wong, R.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2009, 20 (04) : 605 - 608
  • [38] Chemotherapy beyond second-line in advanced gastric cancer
    Kim, Sung Min
    Park, Se Hoon
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (29) : 8811 - 8816
  • [39] New perspectives in the treatment of advanced or metastatic gastric cancer
    Rosati, Gerardo
    Ferrara, Domenica
    Manzione, Luigi
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (22) : 2689 - 2692
  • [40] Taxanes for adjuvant treatment of early breast cancer
    Willson, Melina L.
    Burke, Lucinda
    Ferguson, Thomas
    Ghersi, Davina
    Nowak, Anna K.
    Wicken, Nicholas
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (09):
12345